Ask AI
ProCE Banner Activity

frontMIND: Phase III Trial of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP for Newly Diagnosed DLBCL

Capsule Summary
Slideset

Primary results of the phase III frontMIND study demonstrated significantly improved progression-free survival with tafasitamab plus lenalidomide and R-CHOP vs R-CHOP alone as first-line treatment for high-risk DLBCL and HGBL.

Released: June 23, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with hematologic malignancies. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from studies of hematologic malignancies at ASCO 2026 and EHA 2026 along with expert guidance to optimize personalized care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify patients with hematologic malignancies most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for hematologic malignancies to accelerate their effective incorporation into clinical practice

  • Support informed shared decision-making for patients with hematologic malignancies through accessible discussion of the potential clinical implications of recently presented data at ASCO 2026 and EHA 2026